Fujifilm invests in Suono Bio to advance inflammatory-mediated disease pipeline — 3 insights

Fujifilm Corp. invested an undisclosed amount in Suono Bio to support the company's second-generation drug pipeline.

Here's what you should know:

1. Suono Bio is developing a series of therapies to treat inflammatory diseases.

2. Boston-based Brigham and Women's Hospital gastroenterologist Giovanni Traverso, MD, Polatis Partners Partner Amy Schulman and Carl Schoellhammer, PhD, founded the company.

3. Dr. Schoellhammer said, "I am thrilled that we have the opportunity to forge a long and fruitful relationship with Fujifilm to advance the development of our core technology. Their investment is a critical validation of our platform."

More articles on gastroenterology:
Dr. David Kim pleads guilty to accepting $4.5M in kickbacks — 6 insights
ASC supply chain challenges & opportunities: 3 Qs with Cardinal Health's Marvella Thomas
Possible new ASC one step closer after Louisiana city council passes ordinance

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers